January 10, 2018 – Braeburn today announced that the Company has completed a $110 million mezzanine round of financing led by Wellington Management Company. Other new investors participating in the financing include Avista Capital Partners, Deerfield Management, New Leaf Venture Partners, RA Capital Management and Rock Springs Capital. Apple Tree Partners, the sole investor in Braeburn to date, also participated. Braeburn will use the proceeds to continue to advance the FDA approval process and commercialize CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with OUD.